NASDAQ:MLNT - Melinta Therapeutics Stock Price, Price Target & More

$7.00 +0.05 (+0.72 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$6.95
Today's Range$6.80 - $7.10
52-Week Range$6.50 - $24.25
Volume103,709 shs
Average Volume163,469 shs
Market Capitalization$233.37 million
P/E Ratio-0.32
Dividend YieldN/A
Beta1.38

About Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics logoMelinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MLNT
CUSIP15130J10
Phone312-767-0291

Debt

Debt-to-Equity Ratio0.55%
Current Ratio4.72%
Quick Ratio4.38%

Price-To-Earnings

Trailing P/E Ratio-0.32
Forward P/E Ratio-1.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.86 million
Price / Sales6.48
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book3.03

Profitability

EPS (Most Recent Fiscal Year)($21.86)
Net Income$-58,910,000.00
Net Margins-550.46%
Return on Equity-45.75%
Return on Assets-32.78%

Miscellaneous

Employees300
Outstanding Shares31,330,000

How to Become a New Pot Stock Millionaire

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics (NASDAQ:MLNT) announced its quarterly earnings results on Tuesday, March, 13th. The biotechnology company reported ($1.48) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.89. The biotechnology company had revenue of $4.23 million for the quarter, compared to analyst estimates of $3.28 million. Melinta Therapeutics had a negative return on equity of 45.75% and a negative net margin of 550.46%. View Melinta Therapeutics' Earnings History.

What price target have analysts set for MLNT?

6 brokers have issued twelve-month price objectives for Melinta Therapeutics' shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate Melinta Therapeutics' share price to reach $3.25 in the next year. View Analyst Ratings for Melinta Therapeutics.

Who are some of Melinta Therapeutics' key competitors?

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the folowing people:
  • Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
  • Mr. Daniel Mark Wechsler, Pres & CEO (Age 50)
  • Dr. Thomas A. Steitz Ph.D., Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen Ph.D., Co-Founder

Has Melinta Therapeutics been receiving favorable news coverage?

Media stories about MLNT stock have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Melinta Therapeutics earned a media sentiment score of 0.24 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.05 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Melinta Therapeutics?

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Melinta Therapeutics' stock price today?

One share of MLNT stock can currently be purchased for approximately $7.00.

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $233.37 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 312-767-0291 or via email at [email protected]


MarketBeat Community Rating for Melinta Therapeutics (MLNT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  642
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Melinta Therapeutics (NASDAQ:MLNT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Melinta Therapeutics in the last 12 months. Their average twelve-month price target is $3.25, suggesting that the stock has a possible downside of 53.57%. The high price target for MLNT is $4.00 and the low price target for MLNT is $2.00. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.172.172.171.94
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
11 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.25$3.25$3.25$10.8962
Price Target Upside: 53.57% downside79.37% downside79.37% downside354.01% upside

Melinta Therapeutics (NASDAQ:MLNT) Consensus Price Target History

Price Target History for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ:MLNT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2017GabelliUpgradeSell -> HoldHighView Rating Details
11/30/2017Ladenburg ThalmannUpgradeNeutral -> BuyHighView Rating Details
11/1/2017Robert W. BairdUpgradeUnderperform -> Neutral$2.00N/AView Rating Details
10/26/2017Jefferies GroupReiterated RatingHold -> NeutralN/AView Rating Details
8/10/2017Roth CapitalDowngradeBuy -> Neutral$8.00 -> $4.00HighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$4.00HighView Rating Details
1/12/2017JPMorgan ChaseReiterated RatingHoldN/AView Rating Details
1/2/2017CowenReiterated RatingHoldN/AView Rating Details
1/2/2017Cantor FitzgeraldSet Price TargetBuy$28.00N/AView Rating Details
12/30/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
12/30/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$5.00 -> $5.00N/AView Rating Details
12/29/2016WBB SecuritiesDowngradeBuy -> Hold$40.00 -> $4.00N/AView Rating Details
12/29/2016S&P Equity ResearchBoost Price Target$2.65 -> $3.15N/AView Rating Details
12/20/2016SunTrust BanksDowngradeBuy -> Sell$18.00 -> $5.00N/AView Rating Details
11/8/2016Royal Bank of CanadaReiterated RatingBuy$27.50N/AView Rating Details
11/2/2016UBSDowngradeOutperform -> Market PerformN/AView Rating Details
11/2/2016Raymond JamesReiterated RatingOutperform -> Market PerformN/AView Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Melinta Therapeutics (NASDAQ:MLNT) Earnings History and Estimates Chart

Earnings by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ:MLNT) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.82 EPS
Next Year EPS Consensus Estimate: $-2.71 EPS

Melinta Therapeutics (NASDAQ MLNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018Q4 2017($0.59)($1.48)$3.28 million$4.23 millionViewListenView Earnings Details
11/2/2017Q3 2017($1.00)$1.72 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.32)($0.23)$3.58 million$0.86 millionViewListenView Earnings Details
4/28/2017Q1 2017($0.53)($0.37)$3.55 million$4.87 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.57)($0.60)$4.19 million$7.95 millionViewListenView Earnings Details
10/27/2016Q3($0.64)($0.62)$3.90 million$4.00 millionViewListenView Earnings Details
8/1/2016Q2($0.67)($0.51)$3.89 million$3.42 millionViewN/AView Earnings Details
5/1/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details
7/29/2015Q2($0.41)($0.57)$4.60 million$5.05 millionViewListenView Earnings Details
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details
2/25/2015Q414($0.46)($0.46)$3.50 million$2.47 millionViewListenView Earnings Details
10/29/2014Q314($0.59)($0.34)$1.59 million$7.77 millionViewN/AView Earnings Details
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details
4/25/2013Q1 2013($1.90)($2.10)ViewN/AView Earnings Details
2/28/2013Q4 2012($1.60)($1.30)ViewN/AView Earnings Details
11/8/2012Q312($0.24)ViewN/AView Earnings Details
8/8/2012Q2 2012($1.05)($2.25)ViewN/AView Earnings Details
5/10/2012Q1 2012($2.15)($1.31)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Melinta Therapeutics (NASDAQ:MLNT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Melinta Therapeutics (NASDAQ MLNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.50%
Institutional Ownership Percentage: 37.94%
Insider Trading History for Melinta Therapeutics (NASDAQ:MLNT)
Institutional Ownership by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ MLNT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018Vatera Healthcare Partners LlcDirectorBuy5,777,778$13.50$78,000,003.00View SEC Filing  
3/8/2017Dov A Md GoldsteinDirectorSell150,000$3.55$532,500.0095View SEC Filing  
1/13/2017Dov A Md GoldsteinDirectorSell105,460$3.40$358,564.0095View SEC Filing  
1/6/2017Dov A Md GoldsteinDirectorSell937,600$3.41$3,197,216.0095View SEC Filing  
1/3/2017David N GillDirectorBuy5,000$2.94$14,700.005,000View SEC Filing  
3/1/2016David MooreInsiderBuy500$16.18$8,090.001,500View SEC Filing  
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.5250View SEC Filing  
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.001,100View SEC Filing  
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.001,100View SEC Filing  
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.902,830View SEC Filing  
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Melinta Therapeutics (NASDAQ MLNT) News Headlines

Source:
DateHeadline
Melinta Therapeutics (MLNT) Announces Results from VABOMERE TANGO II TrialMelinta Therapeutics (MLNT) Announces Results from VABOMERE TANGO II Trial
www.streetinsider.com - April 24 at 8:35 AM
Melintas Vabomere shows treatment effect in high-risk patientsMelinta's Vabomere shows treatment effect in high-risk patients
seekingalpha.com - April 23 at 5:02 PM
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in ...Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in ...
globenewswire.com - April 23 at 8:28 AM
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient PopulationsMelinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
finance.yahoo.com - April 23 at 8:28 AM
$13.13 Million in Sales Expected for Melinta Therapeutics (MLNT) This Quarter$13.13 Million in Sales Expected for Melinta Therapeutics (MLNT) This Quarter
www.americanbankingnews.com - April 21 at 2:54 AM
 Analysts Anticipate Melinta Therapeutics (MLNT) to Post -$1.27 EPS Analysts Anticipate Melinta Therapeutics (MLNT) to Post -$1.27 EPS
www.americanbankingnews.com - April 19 at 3:12 PM
Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial ...Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial ...
globenewswire.com - April 17 at 8:54 AM
Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018
finance.yahoo.com - April 16 at 8:31 AM
Melinta Therapeutics (MLNT) Receives "Hold" Rating from Stifel NicolausMelinta Therapeutics (MLNT) Receives "Hold" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 11 at 3:24 PM
Roth Capital Downgrades Melinta Therapeutics (MLNT) to NeutralRoth Capital Downgrades Melinta Therapeutics (MLNT) to Neutral
www.americanbankingnews.com - April 10 at 10:31 PM
Melinta Therapeutics (MLNT) Downgraded by Zacks Investment Research to SellMelinta Therapeutics (MLNT) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 7 at 3:53 PM
New Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/VaborbactamNew Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/Vaborbactam
www.prnewswire.com - April 5 at 5:05 PM
Melinta Therapeutics, Inc. (MLNT) Given Consensus Rating of "Hold" by BrokeragesMelinta Therapeutics, Inc. (MLNT) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 3:26 AM
 Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $13.13 Million Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $13.13 Million
www.americanbankingnews.com - April 4 at 2:46 AM
Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement WeatherMelinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather
finance.yahoo.com - April 3 at 8:41 AM
Melinta Therapeutics (MLNT) Upgraded to "Neutral" at Robert W. BairdMelinta Therapeutics (MLNT) Upgraded to "Neutral" at Robert W. Baird
www.americanbankingnews.com - April 2 at 3:15 PM
Melinta Therapeutics (MLNT) Lowered to Sell at Zacks Investment ResearchMelinta Therapeutics (MLNT) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 31 at 4:56 PM
Equities Analysts Offer Predictions for Melinta Therapeutics, Inc.s FY2022 Earnings (MLNT)Equities Analysts Offer Predictions for Melinta Therapeutics, Inc.'s FY2022 Earnings (MLNT)
www.americanbankingnews.com - March 30 at 7:40 AM
Zacks Investment Research Upgrades Melinta Therapeutics (MLNT) to "Hold"Zacks Investment Research Upgrades Melinta Therapeutics (MLNT) to "Hold"
www.americanbankingnews.com - March 17 at 2:08 PM
Melinta Therapeutics (MLNT) CEO Dan Wechsler on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaMelinta Therapeutics' (MLNT) CEO Dan Wechsler on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 8:34 AM
Melinta Therapeutics (MLNT) Announces  Earnings ResultsMelinta Therapeutics (MLNT) Announces Earnings Results
www.americanbankingnews.com - March 14 at 9:50 AM
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 14 at 9:00 AM
Melinta Therapeutics to Present at Needham & Companys 17th Annual Healthcare Conference - GlobeNewswire (press release)Melinta Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 14 at 9:00 AM
Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare ConferenceMelinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
finance.yahoo.com - March 14 at 9:00 AM
Melinta Therapeutics, Inc. to Host Earnings CallMelinta Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 13 at 8:46 AM
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsMelinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 13 at 8:46 AM
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe - GlobeNewswire (press release)Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe - GlobeNewswire (press release)
globenewswire.com - March 8 at 8:43 AM
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in EuropeMelinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
finance.yahoo.com - March 8 at 8:43 AM
Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 3 at 6:07 PM
Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care ConferenceMelinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 2 at 8:35 AM
Melinta Therapeutics, Inc. (MLNT) Expected to Post Quarterly Sales of $3.28 MillionMelinta Therapeutics, Inc. (MLNT) Expected to Post Quarterly Sales of $3.28 Million
www.americanbankingnews.com - March 1 at 4:54 AM
Melinta Therapeutics (MLNT) Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE in Patients with cUTIMelinta Therapeutics (MLNT) Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE in Patients with cUTI
www.streetinsider.com - February 28 at 8:34 AM
Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
finance.yahoo.com - February 28 at 8:34 AM
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTIMelinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI
finance.yahoo.com - February 27 at 5:42 PM
 Analysts Expect Melinta Therapeutics, Inc. (MLNT) Will Post Earnings of -$0.59 Per Share Analysts Expect Melinta Therapeutics, Inc. (MLNT) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - February 27 at 11:42 AM
Melinta Therapeutics Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for ... - GlobeNewswire (press release)Melinta Therapeutics' Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for ... - GlobeNewswire (press release)
globenewswire.com - February 20 at 8:29 AM
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in ArgentinaMelinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
finance.yahoo.com - February 20 at 8:29 AM
Melinta Therapeutics, Inc. (MLNT) Receives Consensus Rating of "Hold" from AnalystsMelinta Therapeutics, Inc. (MLNT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 13 at 1:38 AM
$3.28 Million in Sales Expected for Melinta Therapeutics, Inc. (MLNT) This Quarter$3.28 Million in Sales Expected for Melinta Therapeutics, Inc. (MLNT) This Quarter
www.americanbankingnews.com - February 12 at 2:26 AM
Melinta Therapeutics, Inc. (MLNT) Short Interest Up 68.2% in JanuaryMelinta Therapeutics, Inc. (MLNT) Short Interest Up 68.2% in January
www.americanbankingnews.com - February 11 at 1:32 AM
Melinta Therapeutics (MLNT) Downgraded by Zacks Investment ResearchMelinta Therapeutics (MLNT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 8 at 12:56 PM
Melinta Therapeutics (MLNT) Lowered to Strong Sell at BidaskClubMelinta Therapeutics (MLNT) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - February 3 at 7:40 PM
Wired News – Melinta Launched Intravenous and Oral Formulations of Baxdela(TM) in the USWired News – Melinta Launched Intravenous and Oral Formulations of Baxdela(TM) in the US
finance.yahoo.com - January 31 at 10:09 AM
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United StatesMelinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
finance.yahoo.com - January 29 at 9:57 AM
 Analysts Expect Melinta Therapeutics, Inc. (MLNT) to Post -$0.59 Earnings Per Share Analysts Expect Melinta Therapeutics, Inc. (MLNT) to Post -$0.59 Earnings Per Share
www.americanbankingnews.com - January 24 at 9:24 PM
Melinta Therapeutics, Inc. (MLNT) Receives Consensus Recommendation of "Hold" from AnalystsMelinta Therapeutics, Inc. (MLNT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 1:32 AM
Vatera Healthcare Partners Llc Acquires 5,777,778 Shares of Melinta Therapeutics, Inc. (MLNT) StockVatera Healthcare Partners Llc Acquires 5,777,778 Shares of Melinta Therapeutics, Inc. (MLNT) Stock
www.americanbankingnews.com - January 9 at 9:38 PM
Zacks: Analysts Expect Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $3.28 MillionZacks: Analysts Expect Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $3.28 Million
www.americanbankingnews.com - January 9 at 3:36 AM
Melinta Therapeutics Completes Acquisition of The Medicines Companys Infectious Disease Portfolio - GlobeNewswire (press release)Melinta Therapeutics Completes Acquisition of The Medicines Company's Infectious Disease Portfolio - GlobeNewswire (press release)
globenewswire.com - January 8 at 8:59 AM
 Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) to Announce -$0.59 EPS Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) to Announce -$0.59 EPS
www.americanbankingnews.com - January 7 at 5:26 PM

SEC Filings

Melinta Therapeutics (NASDAQ:MLNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Melinta Therapeutics (NASDAQ:MLNT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Melinta Therapeutics (NASDAQ MLNT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.